Adjuvant therapy of melanoma with interferon: lessons of the past decade

This publication has 62 references indexed in Scilit:

• Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma
  PLoS Medicine, 2007
• Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses
  Journal of Clinical Oncology, 2006
• Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
  Cancer, 2006
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
  Journal of Clinical Oncology, 2005
• Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
  Published by Elsevier ,2004
• Interferon Alpha as Adjuvant Postsurgical Treatment of Melanoma: A Meta-Analysis
  Dermatology, 2004
• Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma
  Journal of Clinical Oncology, 2004
• Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma
  The Oncologist, 2003
• Current therapy for cutaneous melanoma
  Journal of the American Academy of Dermatology, 1995